Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c-Translating Evidence into Practice

Area of Science:

• Nephrology
• Endocrinology
• Pharmacology

Context:

• Correction of a previously published guideline note regarding SGLT2 inhibitor initiation and continuation criteria.
• Clarification of renal function thresholds for SGLT2 inhibitor therapy in clinical practice.

Purpose:

• To provide accurate guidance on the use of SGLT2 inhibitors based on estimated glomerular filtration rate (eGFR).
• To ensure appropriate patient management and safety concerning SGLT2 inhibitor treatment and renal function.

Summary:

• The original publication's Table 2 note regarding SGLT2 inhibitor initiation has been corrected.
• SGLT2 inhibitor therapies may be initiated in individuals with an eGFR of 60 mL/min/1.73 m².
• Patients already treated with canagliflozin or empagliflozin can continue therapy until their eGFR reaches below 45 mL/min/1.73 m².

Impact:

• Improved clinical decision-making for SGLT2 inhibitor prescribing.
• Enhanced patient safety and optimized therapeutic outcomes in managing conditions like diabetes and heart failure.
• Accurate dissemination of treatment guidelines to healthcare professionals.